Develops targeted cancer medicines that attach drugs to antibodies for patients with cancer, and protein-making technology for pharmaceutical and biotechnology partners.
10-K for FY2025, filed Mar 23, 2026
Pharmaceutical and biotechnology partners work with Sutro through product-focused collaborations and licenses; Vaxcyte receives technical support for vaccine research and development.
10-K for FY2025, filed Mar 23, 2026Enabled through our proprietary XpressCF® and XpressCF+® platforms, we have entered into multitarget, product-focused collaborations with…View ↗
The benefits of our XpressCF® and XpressCF+® platforms have resulted in multiple research and/or development collaborations with leaders in…View ↗
Our XpressCF® and XpressCF+® platforms have also supported Vaxcyte, focused on discovery and development of vaccines for the treatment and…View ↗
No. It lost $191.1M in FY2025.
10-K for FY2025, filed Mar 23, 2026
Pipeline focus
The earlier report centered on luvelta for FolRα-expressing cancers; the latest centers on its tissue-factor ADC program and says luvelta development has ended.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 23, 2026Our most advanced product candidate is STRO-002, or luveltamab tazevibulin, or luvelta, an ADC directed against folate receptor-alpha, or…View ↗
Loading...